Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer

By Lidgren Mathias   Wilking Nils   Jonsson Bengt   Rehnberg Clas  

Acta Oncologica, Vol. 47, Iss. 6, 2008-08 ,pp. : 1018-1028

Informa Healthcare

Access to resources Recommend Favorite

Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis

By Norum J.   Olsen J. A.   Wist E. A.   Lønning P. E.  

Acta Oncologica, Vol. 46, Iss. 2, 2007-01 ,pp. : 153-164

Informa Healthcare

Access to resources Recommend Favorite

Continued Use of Trastuzumab (Herceptin) after Progression on Prior Trastuzumab Therapy in HER-2-Positive Metastatic Breast Cancer

By Pusztai Lajos   Esteva Francisco  

Cancer Investigation, Vol. 24, Iss. 2, 2006-05 ,pp. : 187-191

Informa Healthcare

Access to resources Recommend Favorite

Mechanisms of Trastuzumab Resistance in Breast Cancer

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 9, Iss. 3, 2009-03 ,pp. : 348-355

Bentham Science Publishers

Access to resources Recommend Favorite

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy

By Hurvitz Sara   Dalenc Florence   Campone Mario   O’Regan Ruth   Tjan-Heijnen Vivianne   Gligorov Joseph   Llombart Antonio   Jhangiani Haresh   Mirshahidi Hamid   Tan-Chiu Elizabeth   Miao Sara   El-Hashimy Mona   Lincy Jeremie   Taran Tetiana   Soria Jean-Charles   Sahmoud Tarek   André Fabrice  

Breast Cancer Research and Treatment, Vol. 141, Iss. 3, 2013-10 ,pp. : 437-446

Springer Publishing Company

Access to resources Recommend Favorite